This newsletter activity highlights the latest developments in the treatment of idiopathic pulmonary fibrosis (IPF) presented at an international conference of pulmonologists held in Denver, Colorado in May 2015.

With the introduction of pirfenidone and nintedanib for the treatment of IPF, the field of IPF is rapidly evolving. This conference represents the basis of all information available on IPF, as well as the appropriate application of pirfenidone and nintedanib. Our Faculty Advisors offer insights and key take-away points of the latest research, as well as onsite video commentary of the meeting presentations.

Faculty

Harold R. Collard, MD
Associate Professor of Medicine, Director, Interstitial Lung Disease Program, University of California San Francisco, San Francisco, California

Kevin R. Flaherty, MD, MS
Professor of Medicine, Medical Director, Idiopathic Pulmonary Fibrosis Foundation Clinical Care Site, University of Michigan Health System, Ann Arbor, Michigan

Steven D. Nathan, MD, FCCP  
Medical Director, Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, Virginia

Target audience

Pulmonologists, primary care physicians, and other clinicians with an interest in idiopathic pulmonary fibrosis

Learning objectives

At the conclusion of this activity, participants should be better able to:

• Review the latest data on treatments for idiopathic pulmonary fibrosis (IPF)
• Discuss how therapeutic advances in IPF are guiding research into improved care

Instructions

After reviewing the newsletter, click on and complete the "Quiz" and "Evaluation". You can claim credit and receive your certificate once you have passed the quiz and completed the evaluation.

Supported by an educational grant from Genentech.